These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20805474)

  • 1. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
    Järås M; Johnels P; Hansen N; Agerstam H; Tsapogas P; Rissler M; Lassen C; Olofsson T; Bjerrum OW; Richter J; Fioretos T
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16280-5. PubMed ID: 20805474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
    Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
    Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
    Ågerstam H; Hansen N; von Palffy S; Sandén C; Reckzeh K; Karlsson C; Lilljebjörn H; Landberg N; Askmyr M; Högberg C; Rissler M; Porkka K; Wadenvik H; Mustjoki S; Richter J; Järås M; Fioretos T
    Blood; 2016 Dec; 128(23):2683-2693. PubMed ID: 27621309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
    Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Warfvinge R; Geironson L; Sommarin MNE; Lang S; Karlsson C; Roschupkina T; Stenke L; Stentoft J; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S; Soneji S; Richter J; Karlsson G
    Blood; 2017 Apr; 129(17):2384-2394. PubMed ID: 28122740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
    Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
    De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
    Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD25 on leukemic stem cells in BCR-ABL1
    Sadovnik I; Herrmann H; Eisenwort G; Blatt K; Hoermann G; Mueller N; Sperr WR; Valent P
    Exp Hematol; 2017 Jul; 51():17-24. PubMed ID: 28457753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line.
    Cornelissen JJ; Wognum AW; Ploemacher RE; Frassoni F; Wagemaker G; Hagemeijer A; Löwenberg B
    Leukemia; 1997 Jan; 11(1):126-33. PubMed ID: 9001428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
    Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
    Fathy El-Metwaly N; Aref S; Ayed M; Abdel Hamid M; El-Sokkary AMA
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3237-3243. PubMed ID: 34711000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
    Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
    Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
    Landberg N; Hansen N; Askmyr M; Ågerstam H; Lassen C; Rissler M; Hjorth-Hansen H; Mustjoki S; Järås M; Richter J; Fioretos T
    Leukemia; 2016 Jan; 30(1):253-7. PubMed ID: 26067823
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
    Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
    Askmyr M; Ågerstam H; Hansen N; Gordon S; Arvanitakis A; Rissler M; Juliusson G; Richter J; Järås M; Fioretos T
    Blood; 2013 May; 121(18):3709-13. PubMed ID: 23479569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.